Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 355

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 355
---
 which 
 provides a Phase 2 complementary technology with TuHURA’s current portfolio;                                                                                                                                                                 |

| • |     | The expectation that the Mergers will result in meaningful synergies by combining key assets, capabilities, and                                                         
 intellectual property, as well as ongoing access to world-leading scientific and clinical collaborators, which is expected to deliver long-term value for stockholders; |

| • |     | The TuHURA Board of Directors’ consideration of the strategic fit with KVA12123, Kineta’s VISTA                   
 blocking immunotherapy, to continue developing novel technologies to overcome resistance to cancer immunotherapy; |

| • |     | The expectation that TuHURA will have greater expertise as well as intellectual property and technology access, 
 which will allow TuHURA to accelerate product innovation and investment;                                        |

| • |     | The expectation that TuHURA will have an increased product candidate portfolio; |

| • |     | The recommendation of the Mergers by TuHURA’s senior management team; |

| • |     | That the TuHURA Share Value is fixed and will not fluctuate in the event that the market price of Kineta Common                                   
 Stock increases relative to the market price of TuHURA Common Stock between the date of the Merger Agreement and the consummation of the Mergers; |

| • |     | That TuHURA and Kineta are not required to seek any antitrust regulatory authority clearance or approval of the 
 Mergers.                                                                                                        |

| • |     | That TuHURA will continue to be led by the current strong, experienced TuHURA management team; and |

| • |     | That there are limited circumstances in which the Kineta Board of Directors may terminate the Merger Agreement or 
 change its recommendation that Kineta stockholders approve the Merger Agreement                                   |

223

| Proposal, and if the Merger Agreement is terminated by TuHURA as a result of a change in recommendation of the Kineta Board of Directors or by Kineta in order to enter into a definitive agreement                           
 with a third party providing for the consummation of a Superior Proposal, then in each case Kineta has agreed to pay TuHURA a termination fee of $1 million. For additional information, see the section entitled “The Merger 
 Agreement—Termination”.                                                                                                                                                                                                       |

In addition to considering the factors described above, the TuHURA Board of Directors considered the following additional factors that weighed in favor of the Mergers:

| • |